MEDVi vs Shed: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats Shed overall, scoring 8.3/10 vs 8/10. Shed is more affordable at $149/mo vs $179/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Shed for users who want fast delivery and a streamlined compounded gl.
A side-by-side comparison of MEDVi and Shed covering pricing, scores, medication types, insurance, and more to help you decide.
MEDVi
#9 of 39Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDViShed
#19 of 39Newer GLP-1 provider focused on speed and simplicity — fast approvals, fast shipping, and a clean user experience at a competitive price point.
Visit Shed| Feature | MEDVi | Shed |
|---|---|---|
| Our Score | 8.3/10 | 8/10 |
| Starting Price | $179/mo | $149/mo |
| Medication Type | Compounded | Compounded |
| Insurance Accepted | No | No |
| Best For | Users who want a low entry price with oral and injectable compounded options | Users who want fast delivery and a streamlined compounded GLP-1 experience |
| Ranking | #9 | #19 |
Pros & Cons Compared
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Shed
Pros
- +Industry-leading delivery speed — most patients receive medication within 2-3 days of enrollment
- +$149/mo is competitively priced for an all-inclusive compounded program with good support
- +Streamlined onboarding with no video call — approved and shipped faster than most competitors
- +Clean, modern UX with real-time shipping tracking and easy provider messaging
Cons
- −Compounded semaglutide and tirzepatide only — no brand-name options
- −Newer company (founded 2024) with limited track record and outcome data
- −No insurance billing and no FSA/HSA superbills currently available
- −Clinical support is responsive but less proactive than premium platforms
Our Verdict
MEDVi edges out Shed with a score of 8.3/10 vs 8/10. If budget is your priority, Shed starts at $149/mo compared to MEDVi's $179/mo. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Shed if you want: users who want fast delivery and a streamlined compounded glp-1 experience.